Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2014 - 2026)

Rocket Pharmaceuticals has disclosed Gains from Investment Securities across 13 years of filings, most recently posting $14.2 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $14.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $14.2 million (up 910.59% YoY), and the FY2025 annual result was $12.2 million, up 2940.75% from the prior year.
• Gains from Investment Securities came in at $14.2 million for Q1 2026 at Rocket Pharmaceuticals, up from $5.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $16.4 million in Q2 2025 to a low of -$2.4 million in Q4 2023.
• The 5-year median for Gains from Investment Securities is $1.9 million (2023), against an average of $5.9 million.
• Across the five-year window, Gains from Investment Securities sank 4854.0% in 2023 and jumped 5880.44% in 2024, its largest moves.
• Rocket Pharmaceuticals' Gains from Investment Securities stood at $50000.0 in 2022, then tumbled by 4854.0% to -$2.4 million in 2023, then surged by 99.96% to -$1000.0 in 2024, then surged by 562335.2% to $5.6 million in 2025, then surged by 151.87% to $14.2 million in 2026.
• The last three Gains from Investment Securities figures came in at $14.2 million (Q1 2026), $5.6 million (Q3 2025), and $16.4 million (Q2 2025), per Business Quant data.